A Phase II, Randomized, Controlled, Double-Blind, Multi-Center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 3.75 µg or 7.5 µg of H5N1 Influenza Antigen, in Non-Elderly Adult and Elderly Subjects.

Trial Profile

A Phase II, Randomized, Controlled, Double-Blind, Multi-Center, Study to Evaluate Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines Containing 3.75 µg or 7.5 µg of H5N1 Influenza Antigen, in Non-Elderly Adult and Elderly Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Influenza A virus vaccine-H5N1 (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis; Novartis Vaccines
  • Most Recent Events

    • 09 Feb 2012 Additional locations (Poland, Turkey) added as reported by ClinicalTrials.gov.
    • 09 Feb 2012 Actual end date ( Dec 2009) added as reported by ClinicalTrials.gov.
    • 09 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top